1. Rocephin [package insert] Nutley, NJ: Roche Laboratories Inc; August 2008. [Google Scholar]
2. Trissel LA. Handbook on Injectable Drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; 2007. [Google Scholar]
3. Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm. 1996;53:2611–2613. [PubMed] [Google Scholar]
4. Trissel LA, Gilbert DL, Martinez JF. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 1997;54:1295–1300. et al. [PubMed] [Google Scholar]
5. Trissel LA, Gilbert DL, Martinez JF. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. J Parenter Enteral Nut. 1999;23:67–74. et al. [PubMed] [Google Scholar]
6. Mirtallo JM, Caryer K, Schneider PJ. Growth of bacteria and fungi in parenteral nutrition solutions containing albumin. Am J Hosp Pharm. 1981;38:1907–1910. et al. [PubMed] [Google Scholar]
7. Ambados F. Destabilization of fat emulsion in total nutrient admixtures by concentrated albumin 20% infusion. Aust J Hosp Pharm. 1999;29:210–212. [Google Scholar]
8. Anderson PM, Rogosheske JR, Ramsey NKC. Biological activity of recombinant interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate or total parenteral nutrition solution. Am J Hosp Pharm. 1992;49:608–612. et al. [PubMed] [Google Scholar]
9. Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther. 2006;11:233–236. [PMC free article] [PubMed] [Google Scholar]
10. Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solutions. J Parenter Enteral Nutr. 1985;9:220–224. [PubMed] [Google Scholar]
11. Schilling CG. Compatibility of drugs with a heparin-containing neonatal total parenteral nutrient solution. Am J Hosp Pharm. 1988;45:313–314. [PubMed] [Google Scholar]
12. Kamen BA, Gunther N, Sowinsky N. Analysis of antibiotic stability in a parenteral nutrition solution. Pediatr Infect Dis. 1985;4:387–389. et al. [PubMed] [Google Scholar]
13. Bullock L, Clark JH, Fitzgerald JF. The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures. J Parenter Enteral Nutr. 1989;13:505–509. et al. [PubMed] [Google Scholar]
14. Andreu A, Cardona D, Pastor C. Intravenous aminophylline: in vitro stability of fat-containing TPN. Ann Pharmacother. 1992;26:127–128. et al. [PubMed] [Google Scholar]
15. Niemiec PW, Jr, Vanderveen TW, Hohenwarter MW. Stability of aminophylline injection in three parenteral nutrient solutions. Am J Hosp Pharm. 1983;40:428–432. et al. [PubMed] [Google Scholar]
16. Sykes R, McPherson C, Foulks K. Aminophylline compatibility with neonatal total parenteral nutrition. J Pediatr Pharmacol Ther. 2008;13:76–79. et al. [PMC free article] [PubMed] [Google Scholar]
17. Baptista RJ, Lawrence RW. Compatibility of total nutrient admixtures and secondary antibiotic infusions. Am J Hosp Pharm. 1985;42:362–363. [PubMed] [Google Scholar]
18. Schuetz DH, King JC. Compatibility and stability of electrolytes, vitamins and antibiotics in combination with 8% amino acids solutions. Am J Hosp Pharm. 1978;35:33–44. [PubMed] [Google Scholar]
19. Honisko ME, Fink JM, Militello MA. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm. 2004;61:2415–2418. et al. [PubMed] [Google Scholar]
20. Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 premix) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm. 1994;24:167–170. [Google Scholar]
21. Nahata MC, Zingarelli J, Durrell DE. Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions. J Clin Pharm Ther. 1989;14:53–55. [PubMed] [Google Scholar]
22. Maxipime [package insert] Princeton, New Jersey: Bristol Meyers Squibb Company; December 2003. [Google Scholar]
23. Wade CS, Lampasona V, Mullins RE, Parks RB. Stability of ceftazidime and amino acids in parenteral nutrient solutions. Am J Hosp Pharm. 1991;48:1515–1519. [PubMed] [Google Scholar]
24. Hatton J, Luer M, Hirsch J. Histamine receptor antagonists and lipid stability in total nutrient admixtures. J Parenter Enteral Nutr. 1994;18:308–312. et al. [PubMed] [Google Scholar]
25. Jacobson PA, Maksym CJ, Landvay A, Weiner N, Whitmore R. Compatibility of cyclosporine with fat emulsion. Am J Hosp Pharm. 1993;50:687–690. [PubMed] [Google Scholar]
26. Baptista RJ, Dumas GJ, Bistrian BR. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm. 1985;42:777–778. et al. [PubMed] [Google Scholar]
27. Ohls RK, Christensen RD. Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions. Ann Pharmacother. 1996;30:466–468. [PubMed] [Google Scholar]
28. DiStefano JE, Mitrano JE, Baptista FP. Long-term stability of famotidine 20 mg/mL in a total parenteral nutrient solution. Am J Hosp Pharm. 1989;46:2333–2335. et al. [PubMed] [Google Scholar]
29. Bullock L, Fitzgerald JF, Glick MR. Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions. Am J Hosp Pharm. 1989;46:2321–2325. et al. [PubMed] [Google Scholar]
30. Bullock L, Fitzgerald JF, Glick MR. Stability of famotidine 20 and 50 mg/L in total nutrient admixtures. Am J Hosp Pharm. 1989;46:2326–2329. [PubMed] [Google Scholar]
31. Montoro JB, Pou L, Salvador P. Stability of famotidine 20 and 40 mg/L in total nutrient admixtures. Am J Hosp Pharm. 1989;46:2329–2332. et al. [PubMed] [Google Scholar]
32. Shea BF, Souney PF. Stability of famotidine in a 3-in-1 total nutrient admixture. DCIP. 1990;24:232–235. [PubMed] [Google Scholar]
33. Moshfeghi M, Ciuffo J. Visual compatibility of fentanyl citrate with parenteral nutrient solutions [Letters] Am J Health-Sys Pharm. 1998;55:1194–1197. [PubMed] [Google Scholar]
34. Couch P, Jacobson P, Johnson CE. Stability of fluconazole and amino acids in parenteral nutrient solutions. Am J Hosp Pharm. 1992;49:1459–1462. [PubMed] [Google Scholar]
35. Chen MF, Boyce HW, Triplett L. Stability of the B vitamins in mixed parenteral nutrition solution. J Parenter Enteral Nutr. 1983;7:462–464. [PubMed] [Google Scholar]
36. Barker A, Hebron BS, Beck PR, Ellis B. Folic acid and total parenteral nutrition. J Parenter Enteral Nutr. 1984;8:3–8. [PubMed] [Google Scholar]
37. Louie N, Stennett DJ. Stability of folic acid in 25% dextrose, 3.5% amino acids, and multivitamin solution. J Parenter Enteral Nutr. 1984;8:421–426. [PubMed] [Google Scholar]
38. Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm. 1990;47:2075–2077. [PubMed] [Google Scholar]
39. Outman WR, Mitrano FP, Baptista RJ. Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection. Am J Hosp Pharm. 1991;48:1538–1539. [PubMed] [Google Scholar]
40. Johnson CE, Jacobson PA, Chan E. Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions. Am J Hosp Pharm. 1994;51:503–508. [PubMed] [Google Scholar]
41. Mirtallo JM, Rogers KR, Johnson JA. Stability of amino acids and the availability of acid in total parenteral nutrition solutions containing hydrochloric acid. Am J Hosp Pharm. 1981;38:1729–1731. et al. [PubMed] [Google Scholar]
42. Holt RJ, Siegert SWK, Krishna A. Physical compatibility of ibuprofen lysine injected with selected drugs during simulated Y-site injection. J Pediatr Pharmacol Ther. 2008;13:156–161. [PMC free article] [PubMed] [Google Scholar]
43. Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1991;48:2181–2184. [PubMed] [Google Scholar]
44. Lindsay CA, Dang K, Adams JM, Ou CN, Baker CJ. Stability and activity of intravenous immunoglobulin with neonatal dextrose and total parenteral nutrient solutions. Ann Pharmacother. 1994;28:1014–1017. [PubMed] [Google Scholar]
45. Ishisaka DY, VanVleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm. 1991;48:2442–2443. [PubMed] [Google Scholar]
46. Wan KK, Tsallas G. Dilute iron dextran formulation for addition to parenteral nutrient solutions. Am J Hosp Pharm. 1980;37:206–210. [PubMed] [Google Scholar]
47. Mayhew SL, Quick MW. Compatibility of iron dextran with neonatal parenteral nutrient solutions. Am J Health-Syst Pharm. 1997;54:570–571. [PubMed] [Google Scholar]
48. Tu YH, Knox NL, Biringer JM. Compatibility of iron dextran with total nutrient admixtures. Am J Hosp Pharm. 1992;49:2233–2235. et al. [PubMed] [Google Scholar]
49. Vaughan LM, Small C, Plunkett V. Incompatibility of iron dextran and a total nutrient admixture. Am J Hosp Pharm. 1990;47:1745–1746. [PubMed] [Google Scholar]
50. Athanikar N, Boyer B, Deamer R. Visual compatibility of 30 additives with a parenteral nutrient solution. Am J Hosp Pharm. 1979;36:511–513. et al. [PubMed] [Google Scholar]
51. Feigin RD, Moss KS, Shackelford PG. Antibiotic stability in solutions used for intravenous nutrition and fluid therapy. Pediatrics. 1973;51:1016–1026. [PubMed] [Google Scholar]
52. Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc. 2000;40:515–519. [PubMed] [Google Scholar]
53. Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm. 1991;48:123–125. [PubMed] [Google Scholar]
54. Bhatt-Mehta V, Rosen DA, King RS, Maksym CJ. Stability of midazolam hydrochloride in parenteral nutrient solutions. Am J Hosp Pharm. 1993;50:285–288. [PubMed] [Google Scholar]
55. Akkerman SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. solutions. Am J Health-Syst Pharm. 1999;56:63–68. [PubMed] [Google Scholar]
56. Veltri MA, Conner KG. Physical compatibility of milrinone lactate injection with intravenous drugs commonly used in the pediatric intensive care unit. Am J Health-Syst Pharm. 2002;59:452–454. [PubMed] [Google Scholar]
57. Bhatt-Mehta V, Paglia RE, Rosen DA. Stability of propofol with parenteral nutrient solutions during simulated Y-site injection. Am J Health-Syst Pharm. 1995;52:192–196. [PubMed] [Google Scholar]
58. Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm. 1992;49:402–406. [PubMed] [Google Scholar]
59. Dahl GB, Svensson L, Kinnander NJ, Zander M, Bergstrom UK. Stability of multivitamins in soybean oil fat emulsion under conditions simulating intravenous feeding of neonates and children. J Parenter Enteral Nutr. 1994;18:234–239. [PubMed] [Google Scholar]
